Holen Sie sich die Stockscreener-App
13.78
4.97%
-0.72
Handel nachbörslich:
14.60
0.82
+5.95%
Schlusskurs vom Vortag:
$14.50
Offen:
$14.74
24-Stunden-Volumen:
3.17M
Relative Volume:
1.64
Marktkapitalisierung:
$2.20B
Einnahmen:
$276.98M
Nettoeinkommen (Verlust:
$-59.46M
KGV:
-34.56
EPS:
-0.3987
Netto-Cashflow:
$-48.95M
1W Leistung:
-1.85%
1M Leistung:
-6.95%
6M Leistung:
-21.66%
1J Leistung:
+37.39%
1-Tages-Spanne:
$13.64
$14.83
1-Wochen-Bereich:
$13.22
$14.83
52-Wochen-Spanne:
$8.375
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
13.78 | 2.32B | 276.98M | -59.46M | -48.95M | -0.3987 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised - Investing.com
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call - Benzinga
Adaptive Biotechnologies: Q1 Earnings Snapshot - marketscreener.com
[10-Q] Adaptive Biotechnologies Corp Quarterly Earnings Report - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) lifts 2026 MRD outlook after 35% Q1 revenue growth - Stock Titan
Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain - Stock Titan
MSN Money - MSN
Adaptive Biotechnologies earnings on deck after 55% revenue surge - Investing.com
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares - Investing.com
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions - Yahoo Finance
Adaptive Biotechnologies Corp (HAM:1HM) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Adaptive Biotechnologies Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Valuation: Significantly Overvalued - GuruFocus
Adaptive Biotechnologies Corp Stock Intrinsic Values | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Historical Valuations | HAM:1HM - GuruFocus
Adaptive Biotechnologies Corp Stock Operating Data - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Adaptive Biotechnologies Corp Stock Baskets | HAM:1HM - GuruFocus
Who's Buying or Selling Adaptive Biotechnologies Corp (HAM:1HM) Stock Today? - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM)Valuation Measures & Financial Statistics - GuruFocus
Adaptive Biotechnologies Corp Stock Warning Signs - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) DCF Valuation - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock Earnings Transcripts - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock Price, Trades & News - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Dividend - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock Price & 30 Year Financial Data - GuruFocus
Adaptive Biotechnologies Corp (HAM:1HM) Stock News, Headlines & Updates - GuruFocus
Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock By Investing.com - Investing.com India
Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock - Investing.com
Adaptive Biotechnologies (ADPT) exec trades shares under Rule 10b5-1 plan - Stock Titan
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means - AOL.com
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock By Investing.com - Investing.com Australia
Time To Buy? Stock Analysis: NIO, XPeng XPEV, Costco, Adaptive Biotechnologies ADPT, GE (JtamyA8uVU) - Fathom Journal
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock - Investing.com
Adaptive Biotechnologies (ADPT) president sells 57K shares, exercises options - Stock Titan
[ARS] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) 2026 proxy details and 2025 performance - Stock Titan
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock By Investing.com - Investing.com India
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock - Investing.com
Adaptive Biotechnologies (ADPT) COO sells shares, exercises options under 10b5-1 plan - Stock Titan
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? - AOL.com
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies - Intellectia AI
Adaptive Biotechnologies: Strong Sequencing, Weak Margin Of Safety (NASDAQ:ADPT) - Seeking Alpha
Is Adaptive Bio (ADPT) stock stronger than peers (Investor Interest) 2026-04-18Investment Signal Network - Cổng thông tin điện tử tỉnh Lào Cai
Adaptive Biotechnologies Hits Day Low of $13.37 Amid Price Pressure - Markets Mojo
Adaptive Biotechnologies president Rubinstein sells $826k in ADPT stock By Investing.com - Investing.com UK
Adaptive Biotechnologies president Rubinstein sells $826k in ADPT stock - Investing.com
Adaptive Biotechnologies (ADPT) COO exercises options and sells 57,180 shares - Stock Titan
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 - The Manila Times
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):